Years after the biopharmaceutical industry stepped up to create COVID-19 vaccines as the virus spiraled into a global ...

We recently published a list of Jim Cramer Discussed These 6 Stocks Recently. In this article, we are going to take a look at ...

For GSK’s Ramakrishnan, who has served as CDTO since 2021, the biggest challenge was helping her company get a head start in ...

The FDA approved GSK’s drug for a common type of urinary tract infection (UTI) in women and adolescent girls, one of five new ...

GSK is opening the door to a new era in urinary tract infection (UTI) treatment with its Blujepa, the first in a new class of ...

GSK PLC closed 18.56% short of its 52-week high of £18.24, which the company achieved on May 16th.

GSK (GSK) plc announced that the U.S. Food and Drug Administration has approved Blujepa for the treatment of female adults and pediatric ...

According to Benzinga Pro, GSK's peer group average for short interest as a percentage of float is 4.22%, which means the company has less short interest than most of its peers. Did you know that ...

Pharma major GSK (LSE: GSK) on Tuesday said its urinary tract infection treatment gepotidacin, under the brand name Blujepa, ...

GSK PLC closed 15.77% below its 52-week high of £18.24, which the company reached on May 16th.

Barclays analyst Emily Field maintained a Hold rating on GlaxoSmithKline (GSK – Research Report) today and set a price target of £14.50. The ...

UK pharma major GSK (LSE: GSK) today announced a major new research collaboration with the UK Dementia Research Institute (UK ...